WuXi Biologics Plans to Buy Back Up to US$400 Million of Shares
By Megan Cheah
WuXi Biologics (Cayman) is proposing to repurchase up to US$400 million of its shares in the open market, signaling confidence in its business outlook.
The buybacks will be conducted "from time to time" in the open market, the Hong Kong-listed contract research, development and manufacturing company said Tuesday. The company has a repurchase mandate to buy back around 406 million shares, or roughly 10% of its issued shares as of its last annual general meeting, on the Hong Kong stock exchange.
The company said it proposed the repurchase as the current trading price of the shares doesn't reflect their intrinsic value or the actual business prospects of the company.
The proposed share repurchase is to "demonstrate the company's confidence in its own business outlook and prospects," added WuXi Biologics, which provides services for the pharmaceutical industry.
Shares of WuXi Biologics closed Friday 0.4% lower at 32.72 Hong Kong dollars, equivalent to US$4.18, before the announcement. The stock is up 4.1% year to date.
Write to Megan Cheah at megan.cheah@wsj.com
(END) Dow Jones Newswires
May 25, 2026 21:27 ET (01:27 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States